As in many renewing normal tissues and in neoplastic disorders, growth of hepatocellular carcinoma (HCC) is determined by the difference between cell proliferation and cell death. Among factors operational in tissue cell loss, apoptosis-as a form of programmed cell death-holds a particularly important place. Apoptosis is genetically programmed and is now recognised as a widespread phenomenon that counterbalances proliferation to preserve tissue homeostasis. Whereas mitotic figures in tumours are easily detectable, assessment of apoptotic cells in tissue sections using cytomorphological criteria is difficult, because of the frequently disrupted architecture in tumours and the presence of several different cell types. Furthermore, the detection and quantification of apoptosis is hampered by the fact that cell shrinkage, nuclear condensation, and chromatin fragmentation usually occur only during advanced stages of the process, and the half life of frankly apoptotic cells in tissues is thought to be in the region of several hours at most.' The reproducible identification of apoptotic cells in malignant tumours of the liver is important in so far as programmed cell death also occurs in later stages of carcinoma development.2 There is evidence that apoptosis does not occur at random in the liver. During regression of hyperplasia, non-proliferating hepatocytes seem to be preferred for apoptosis, and cells in putative preneoplastic foci of rat liver show a much higher rate of apoptosis than normal hepatocytes.3`6 Furthermore, after initiation in the liver, many initiated cells may undergo apoptosis and never develop into preneoplastic foci, so that apoptosis appears to determine the efficiency of initiation; early preneoplastic foci in the promotion stage also show enhanced states of apoptosis.6 Based on these earlier observations and the difficulties arising from the employment of conventional methods only, it is necessary to identify apoptotic cells in an early stage of this active pathway.8 One method of achieving this is the use of in situ DNA end labelling,9 '" which exploits the presence of DNA breaks that occur in cells undergoing apoptosis. The 
IMMUNOHISTOCHEMISTRY
Proliferating cell nuclear antigen (PCNA) immunostaining'9-22 was performed using the APAAP procedure. Tissue sections were deparaffinised and rehydrated (Tris-NaCl buffer: 0.1% Tris and 1% NaCl, pH 7.4, Merck). The sections were then exposed to 3% bovine serum albumin (BSA; Merck) in Tris-NaCl buffer with 0.1 ml/ml normal horse serum and 0.1% NaN3 for 45 minutes at room temperature. Afterwards, the preparations were incubated with a primary mouse monoclonal antibody directed against PCNA (Dako-PCNA, PC 10) for one hour. A dilution of 1:50 in Tris-NaCl buffer containing 0.1% NaN3 was used. Rabbit antimouse immunoglobulin (Dako) at a dilution of 1:30 and APAAP mouse monoclonal antibody (Dako) at a dilution of 1:50 were applied for 45 minutes each. Following the respective incubations, the sections were rinsed three times in Tris-NaCl buffer. All incubations were performed in a humidified environment at room temperature. The alkaline phosphatase reaction was run for 20 minutes in New Fuchsin substrate solution, and the reaction was stopped by rinsing the sections in cold tap water. Finally, the sections were counterstained with haematoxylin (Merck) and mounted with Aquadex (Merck). The primary antibody was substituted with normal mouse serum (Dako) in protein concentration of 0.06 mg/ml Tris-NaCl buffer for negative control sections, and all other steps were performed for these preparations. As a positive control an HCC preparation strongly expressing PCNA was processed in parallel to each incubation step.
For p53 immunohistochemistry, the following antibodies were employed: CM-I (Medac Diagnostica, dilution 1:200); PAb-1801 (Oncogene Sciences, dilution 1:20); PAb-240 (Oncogene Sciences, dilution 1:10); and PAb-421 (Oncogene Sciences, dilution 1:5); DO-7 (Dako dilution 1:100). Antibody CM-1 is raised against recombinant human wild-type p53 protein; antibody PAb-1 801 recognises a denaturation resistant epitope in human p53 protein located between amino acid residues 32 and 79, PAb-240 recognises an epitope localised between amino acids 156 and 335, PAb-421 recognises an epitope between amino acids 370 to 378, and DO-7 recognises an epitope between amino acids 35 to 45 .18 For PAb-1801, PAb-240, PAb-421, and DO-7, immunostaining was performed using a modified APAAP procedure as given above for PCNA, whereas the p53 CM-1 antibody was assessed by use of a modified avidin-biotin complex (ABC) technique, as previously described in a p53 study performed by our group. "8
For the in situ visualisation of apoptotic cells, ISEL was used according to a previously published method.9
Paraffin sections (4 gm thick) were affixed to Super Frost/plastic slides (Menzel-Glaser, Germany). Deparaffination was performed by heating the sections for four hours at 58°C. Hydration was executed by transfering the slides through the following solutions: twice in xylene bath for 10 minutes each, twice in 100% ethanol for five minutes each, and then for three minutes in 96%, 70%, and 35% ethanol, and three times in double distilled water. Fresh solvents were used in each case, as even traces of impurities may interfere with the reactions. The prepared paraffin sections were then digested by incubation with 5 jg/ml proteinase K (Sigma) for 20 minutes at room temperature, and washed three times in double distilled water for five minutes each. Peroxidase and DNAses were inactivated by incubating the sections in 2% H202 for five minutes at room temperature. Afterwards, sections were rinsed with double distilled water three times. The TdT (terminal deoxynucleotidyl transferase; nucleoside-triphosphate: DNA deoxynucleotidyl exotransferase; EC 2.7.7.31) reaction mix (30 mM Trizma base, pH 7.2, 140 mM sodium cacodylate, 1 M cobalt chloride, TdT enzyme 0.2,M/ml, and digoxygenin conjugated or biotinylated dUTP in ENTP buffer; Boehringer Mannheim, Germany) was added to cover the sections and then incubated in humidified atmosphere at 370C for 60 minutes. The reaction was stopped by transferring the slides to 2 x SSC buffer for 10 minutes (twice) and TB buffer (300 mM sodium chloride, 30 mM sodium citrate) for 10 minutes (twice), and sections were incubated 30 minutes in 1 % blocking reagent (Boehringer Mannheim) at room temperature, followed by washing in phosphate buffered saline twice for five minutes. Sections were covered with Extra-avidin alkaline phosphatase ( counted within the areas of interest. The number of positive nuclei per 100 nuclei analysed was used as a PCNA labelling index (PCNA-LI) and a TdT labelling index (TdT-LI), respectively. Within HCC, five areas of interest were randomly chosen. For cirrhotic nodules containing liver cell dysplasia, five areas of dysplastic hepatocytes were identified and, within these subsets, cells to be counted were randomly chosen. In each area of HCC and liver cell dysplasia, 1000 cells were analysed. For normal control biopsies, the same strategy was employed.
ASSESSMENT OF P53 PROTEIN IMMUNOREACTIVITY
For each of the five anti-p53 protein antibodies employed, immunoreactivity was recorded as either positive or negative, based on the presence or absence of clearly red or brown reaction product for the APPAP and ABC assays, respectively. Neoplastic and nonneoplastic lesions were accepted to be positive when, within and are of interest, at least 10% of cells were p53 immunoreactive. Pink or beige/ yellowish reaction products were classified as negative.
STATISTICAL ANALYSIS
For the statistical analysis of differences in apoptosis labelling between groups, KruskalWallis one way and Kolmogorov-Smirnov analyses were employed. A p value of less than 0.05 was accepted as statistically significant.
Results

HISTOLOGICAL FINDINGS
In Type   T+SC  T+P+SC  T+SC  p  C  T  T  T  T  T  T  T  T+P  p  C  C  T+C  T  p  T  T+C  p  T  T  T  T  T   P+C+SA  T  T+SC  F  SA  SC+F  C+SA  T  T Immunoreactivity for p53 protein in HCC was predominantly nuclear (fig 1) . Overall positivity for p53 protein in HCC (all five anti- bodies included) was 78.3%, but we observed differences from one antibody to another. The highest yield was found with PAb-1801 (76.5%), followed by CM-1 (62.1%), PAb-240 (16.2%), PAb-421 (10.8%), and DO-7 (10.8%). Of the 37 HCC, three were positive with all five antibodies, two with three, 18 with two, and seven with only one. These differences in reactivity may in part be due to different epitopes recognised by the five antibodies (see above). For liver cell dysplasia and regenerating cells associated with HCC (all four groups taken together), 18 out of 37 cases were immunoreactive for p53 protein, SRLC being the most commonly positive (10/37). In contrast to the group with HCC, p53 protein staining in the group not associated with HCC yielded higher values for both SRLC and liver cell dysplasia (46/66). No staining was detected in control liver biopsies.
APOPTOTIC RATE OF HCC
In human tonsils used as positive controls, strong TdT labelling was seen in phagocytosed nuclear fragments occurring in the cytoplasm of germinal centre macrophages (fig 2) . These nuclear fragments (so called tingible bodies) represent structures derived from lymphocytes undergoing apoptosis. In HCC, TdT labelling was clearly seen in the form of a strong reaction product in carcinoma cell nuclei (fig 3) . Positive cells sometimes occurred as small clusters. In most situations, reactivity was restricted to nuclei, and no cytoplasmic staining was detectable, but with some exceptions. HCC cells undergoing morphologically visible decay, characterised by loss of cellular integrity and shrinkage of nuclei, sometimes showed staining of both nucleus and cytoplasm. This phenomenon is most probably the result of entry of DNA fragments from a damaged and permeabilised nucleus into the cytoplasm. Furthermore, HCC cells shed from carcinoma tissue which had rounded up to form condensed spherical structures (apoptotic bodies) showed strong overall staining, including the nuclear remnant and the dense cytoplasmic rim. Interestingly, a few polymorphic HCC cells showing no morphological signs of damage had both nuclear and cytoplasmic staining (fig 4) . Cytoplasmic staining and staining of nuclear fragments also occurred in areas of typical tumour necrosis (not shown). This phenomenon is most probably due to chromatin decay in necrosis and therefore to the production of numerous reactive DNA sites freely available in the areas involved. Nuclear TdT labelling was detectable in all types of HCC and there was no difference between them ( The correlations of TdT-LI and PCNA-LI with respect to p53 protein immunoreactivity are listed in table 2. The apoptotic rate and the proliferation rate were significantly higher in p53 positive cases of HCC.
APOPTOTIC RATE OF DYSPLASTIC LIVER CELLS
In comparison with HCC, very few nuclei of normal looking hepatocytes were TdT positive, as in the normal liver tissue used as a control. Among pathological hepatocytes occurring in cirrhotic nodules, nuclear TdT labelling was only observed in SRLC and LLCDo cells, and not in liver cell dysplasia of the SLCD and LLCDe types. Correlations of TdT with PCNA-LI and p53 protein immunoreactivity of liver cell dysplasia cells are given in table 2, with cases subdivided according to whether HCC was present or not.
Discussion
Apoptosis is recognised as an important function in the cell turnover of normal and neoplastic tissues,' 23 and has been shown to play a significant role in normal liver and in several types of hepatobiliary disease." 24 25 Apoptosis takes place naturally in the liver, albeit at a very low rate.26 It has been shown that increased hepatocyte proliferation induced by several factors is normally followed by increased apoptosis.27 As both the development and the growth of tumours is determined by the difference between cell proliferation and cell loss, it can be expected that apoptosis is involved in the establishment of liver cancer. In fact, it has been shown that apoptosis occurs in hepatocellular tumours,28 that carcinogens exert their carcinogenic effects not only through stimulation of cell replication but also by modulating the incidence of apoptosis,6 and that apoptosis occurs in preneoplastic lesions26 29 30 and in rat hepatoma cells grown in ascites form.3' Apoptosis has recently been studied in rat liver tumours by the use of quantitative methods,32 33 12 Hino N, Higashi T, Nouso K, Nakatsukasa H, Tsuji T.
[n contrast, both 
